Literature DB >> 21494460

Management of schizophrenia : an update.

P Kulhara1.   

Abstract

Introduction of potent antipsychotics for the treatment of schizophrenia not only brought changes in the outlook for management of this disorder but also infused optimism and hope. However, substantial number of patients fail to respond to conventional antipsychotics thus creating a class of patients who are termed as treatment resistant, treatment refractory or difficult to treat patients. This update focuses on such patients and provides description of various options for their management Though atypical antipsychotics offer respite to a vast number of such difficult to treat patients, their efficacy is perhaps over-emphasised. Conversely, the potential of psychosocial therapies in such patients has not been fully exploited. Management of such patients in the community is a challenge and in taking up this gauntlet, a judicious mix of pharmacotherapy and psychosocial intervention strategies, close monitoring of the patients with a view to detect prodromes of relapse and early intervention are likely to play increasingly important part.

Entities:  

Keywords:  Schizophrenia; management; psycho-social; psychophanvacology

Year:  1998        PMID: 21494460      PMCID: PMC2965836     

Source DB:  PubMed          Journal:  Indian J Psychiatry        ISSN: 0019-5545            Impact factor:   1.759


  68 in total

1.  A controlled study of education about drug treatment in schizophrenia.

Authors:  R Macpherson; B Jerrom; A Hughes
Journal:  Br J Psychiatry       Date:  1996-06       Impact factor: 9.319

Review 2.  Treatment of schizophrenia.

Authors:  J M Kane; T H McGlashan
Journal:  Lancet       Date:  1995-09-23       Impact factor: 79.321

3.  London-East Anglia randomised controlled trial of cognitive-behavioural therapy for psychosis. II: Predictors of outcome.

Authors:  P Garety; D Fowler; E Kuipers; D Freeman; G Dunn; P Bebbington; C Hadley; S Jones
Journal:  Br J Psychiatry       Date:  1997-11       Impact factor: 9.319

4.  Life events preceding relapse of schizophrenia.

Authors:  M K Das; P L Kulhara; S K Verma
Journal:  Int J Soc Psychiatry       Date:  1997

5.  London-East Anglia randomised controlled trial of cognitive-behavioural therapy for psychosis. I: effects of the treatment phase.

Authors:  E Kuipers; P Garety; D Fowler; G Dunn; P Bebbington; D Freeman; C Hadley
Journal:  Br J Psychiatry       Date:  1997-10       Impact factor: 9.319

6.  The influence of family and social factors on the course of psychiatric illness. A comparison of schizophrenic and depressed neurotic patients.

Authors:  C E Vaughn; J P Leff
Journal:  Br J Psychiatry       Date:  1976-08       Impact factor: 9.319

Review 7.  Drug treatment of resistant schizophrenia. Limitations and recommendations.

Authors:  A E Farmer; A Blewett
Journal:  Drugs       Date:  1993-03       Impact factor: 9.546

8.  Immigrant families coping with schizophrenia. Behavioral family intervention v. case management with a low-income Spanish-speaking population.

Authors:  C Telles; M Karno; J Mintz; G Paz; M Arias; D Tucker; S Lopez
Journal:  Br J Psychiatry       Date:  1995-10       Impact factor: 9.319

9.  Compliance with treatment in schizophrenia: a drug intervention program in a developing country.

Authors:  M S Razali; H Yahya
Journal:  Acta Psychiatr Scand       Date:  1995-05       Impact factor: 6.392

10.  Personal therapy: a disorder-relevant psychotherapy for schizophrenia.

Authors:  G E Hogarty; S J Kornblith; D Greenwald; A L DiBarry; S Cooley; S Flesher; D Reiss; M Carter; R Ulrich
Journal:  Schizophr Bull       Date:  1995       Impact factor: 9.306

View more
  2 in total

1.  Schizophrenia research: Indian scene in last decade.

Authors:  Ajit Avasthi; Gagandeep Singh
Journal:  Indian J Psychiatry       Date:  2004-04       Impact factor: 1.759

2.  Clinical Practice Guidelines for Management of Schizophrenia.

Authors:  Sandeep Grover; Subho Chakrabarti; Parmanand Kulhara; Ajit Avasthi
Journal:  Indian J Psychiatry       Date:  2017-01       Impact factor: 1.759

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.